Traverso

Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare diseases. The company's lead product, Filspari (sparsentan), is a first-in-class non-immunosuppressive therapy approved to reduce proteinuria in adults with primary IgA nephropathy. Travere is also advancing a late-stage pipeline that includes pegtibatinase for classical homocystinuria and other candidates for rare kidney and metabolic disorders. By combining internal research and development with strategic partnerships, the company aims to address high unmet medical needs within the rare disease community.